SCNI שווי כולל של נכסי החברה Scinai Immunotherapeutics Ltd

The price action of the aggregate assets of Scinai Immunotherapeutics (SCNI), whose business is based on the development of immune drugs, demonstrates a value of 14.53. While demand for medicine remains stable, sanctions and geopolitics could disrupt raw material logistics. Financial pressure is mounting due to R&D costs in the absence of sales and the risk of clinical trial failure. Meanwhile, the regulator, rather than economic cycles, determines the company's success.

By advancing immunological pharma through partnerships with institutes and laboratories to create nanobodies, Scinai Immunotherapeutics (SCNI) optimizes resources, which is reflected in total assets via ROA. This indicator, calculated inversely through return on equity, measures the overall scale of assets and liabilities, allowing investors to assess the real capacity of the business and avoid overpaying when purchasing the asset at local peaks.